Indole carbamates as leukotriene antagonists
CA 2234239 C · Owner: Pfizer Limited · Inventors: Marfat, Anthony; Brown, Matthew F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I) wherein R1 and R2 are as defined is useful in the , treatment of asthma rheumatoid arthritis, osteoarthritis, bronchitis chronic , obstructive airways disease, psoriasis allergic rhinitis, atopic dermatitis, shock and other inflammatory diseases. Pharmaceutical compositions containing the compound and methods of blocking the leukotriene D4 receptor with the compound are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 26, 1996 and granted May 20, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 26, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 26, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.